Sonoma BioTherapeutics Company
Sonoma BioTherapeutics develops adoptive Treg therapies cell for autoimmune.
Investors
.jpeg)
Technology:
Atrificial Vectors and Immune Cells, Cell-based gene therapy
Industry:
Atrificial Vectors and Immune Cells, Private
Headquarters:
South San Francisco, California, United States
Founded Date:
2020-01-01
Employees Number:
101-250
Investors Number:
24
Total Funding:
365000000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2023-03-28
Last Funding Type:
Corporate Round
Register and Claim Ownership